Rheumatoid arthritis can be treated with glucocorticoid-targeted therapies

Primary tabs

Rheumatoid arthritis can be treated with glucocorticoid-targeted therapies

In the treatment of inflammatory diseases, the beneficial effects of glucocorticoids can't be neglected. In rheumatoid arthritis (RA), these drugs are widely used as they can effectively decrease the signs and symptoms of the disease and exert disease-modifying effects. Nonetheless, both patients and physicians frequently link glucocorticoids with a variety of adverse effects which affect the adherence to the therapy. Due to this contradictory nature of these drugs, many new glucocorticoids or glucocorticoid receptor ligands are being developed to improve their benefit-risk balance.

Strehl C, et al., discussed the current approaches to achieve this goal, including an optimized application of conventional glucocorticoids and the development of novel formulations aimed at minimizing adverse effects while keeping or even enhancing the anti-inflammatory efficacy.

According to the expert opinion, glucocorticoids whether conventional or modified/delayed-release formulations had been so far compelling in clinical practice and their widespread use will thus continue. They are not likely to be replaced by novel drugs in the near future. However, some investigational preparations are promising, and consequences obtained from currently ongoing clinical trials in humans are eagerly anticipated. Hence, these developmental activities leading to a further improvement of the benefits-risk balance of glucocorticoids or glucocorticoid receptor ligands are expected.


Expert Opin Investig Drugs.

Link to the source:


The original title of the article:

Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis


Cindy Strehl et al.

Therapeutic, Rheumatoid arthritis, Joints, Glucocorticoid-targeted therapies
Log in or register to post comments